南美超级胎牛血清999尝鲜特惠
转染试剂低至5折
基质胶阶梯特惠
积分商城,好礼送不停
南美超级胎牛血清999尝鲜特惠
转染试剂低至5折
基质胶阶梯特惠
积分商城,好礼送不停

翌圣生物 Yeasen|生命科学试剂与诊断原料一站式平台

Xiaoyaosan Ameliorates Stress-Induced MASH via Modulating IL-1R1/RXRα-Mediated Liver-Brain Crosstalk

Yi Zhang, Xiaoru Luo, Shuya Wu, Yiheng Qin, Qianyin Xue, Wenjuan Ye, Shibing Hou, Buping Liu, Danping Huang, Weiqu Yuan, Haiqing Ao, Guangdong Tong, Mianmian Liao

Journal:JOURNAL OF ETHNOPHARMACOLOGY

IF:5.4

DOI:10.1016/j.jep.2026.121585

PMID:

Published:2026-03-28

research field:分子生物学中医药学肝脏病学神经免疫学民族药理学代谢性疾病

Abstract

Ethnopharmacological relevance Metabolic dysfunction-associated steatohepatitis (MASH) constitutes an advancing hepatic disorder endangering worldwide well-being with scarce therapeutic options. Social stress, an important trigger of MASH, exacerbates hepatic inflammation and lipid metabolism disorders. Xiaoyaosan (XYS), a classical herbal formula traditionally used to soothe the liver and relieve depression, to strengthen the spleen and regulate metabolism, is clinically used for emotional and metabolic imbalances, but its mechanism in stress-induced MASH remains unclear. Aim of the study Building upon its traditional use in managing stress-related disorders, this study aims to elucidate the therapeutic mechanism by which XYS ameliorates psychosocial stress-induced MASH, thereby providing a mechanistic foundation for its pharmacological application in metabolic disorders with psychosomatic components. Materials and methods A MASH mouse model was established via chronic unpredictable mild stress (CUMS) combined with choline-deficient amino acid-defined high-fat diet (CDAHFD). XYS’s efficacy was evaluated by behavioral assessment (open field test), hepatic histopathology (HE, Oil Red O, Masson/Sirius Red, IHC staining), biochemical analyses (ALT, AST, TG), and ELISA (serum/liver IL-1β, TNF-α). Multi-omics (lipidomics, proteomics, transcriptomics) screened key targets/pathways, validated by rt-qPCR, WB, Co-IP, and IF. Results XYS improved mouse stress status and dose-dependently reduced hepatic lipid deposition, fibrosis, and inflammation. Multi-omics revealed XYS reshaped lipid metabolism by inhibiting the TLR4/IL-1R1/MYD88 axis, upregulating PGC1-α/RXRα, and correcting the reduced binding of RXRα to both PPARα and PGC1-α. Conclusion XYS effectively treats CUMS-induced MASH, likely by inhibiting IL-1R1-mediated inflammation, restoring the reduced binding of RXRα to PPA

本文使用的Yeasen产品

购物车
客服
转染试用